{"id":"https://openalex.org/W602441419","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","title":"No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw in the EVIDENCE Study (P7.220)","display_name":"No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw in the EVIDENCE Study (P7.220)","publication_year":2015,"publication_date":"2015-04-06","ids":{"openalex":"https://openalex.org/W602441419","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","mag":"602441419"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.84.14_supplement.p7.220","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012376027","display_name":"Patricia Katherine Coyle","orcid":"https://orcid.org/0000-0002-3801-6177","observed_orcids":["https://orcid.org/0000-0002-3801-6177"]},"institutions":[{"id":"https://openalex.org/I59553526","display_name":"Stony Brook University","ror":"https://ror.org/05qghxh33","country_code":"US","type":"education","lineage":["https://openalex.org/I59553526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia Coyle","raw_affiliation_strings":["Department of Neurology Stony Brook University Stony Brook NY United States","2Department of Neurology Stony Brook University Stony Brook NY United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology Stony Brook University Stony Brook NY United States","institution_ids":["https://openalex.org/I59553526"]},{"raw_affiliation_string":"2Department of Neurology Stony Brook University Stony Brook NY United States","institution_ids":["https://openalex.org/I59553526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091507790","display_name":"Juanzhi Fang","orcid":"https://orcid.org/0000-0002-1448-6190","observed_orcids":["https://orcid.org/0000-0002-1448-6190"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juanzhi Fang","raw_affiliation_strings":["EMD Serono, Inc. Rockland MA United States","1EMD Serono, Inc. Rockland MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"1EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110488899","display_name":"Ali Hassan","orcid":"https://orcid.org/0009-0007-2982-9110","observed_orcids":["https://orcid.org/0009-0007-2982-9110"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ali Hassan","raw_affiliation_strings":["EMD Serono, Inc. Rockland MA United States","1EMD Serono, Inc. Rockland MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"1EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109037168","display_name":"Choon Cha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Choon Cha","raw_affiliation_strings":["EMD Serono, Inc. Rockland MA United States","1EMD Serono, Inc. Rockland MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"1EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010771032","display_name":"Fernando Dangond","orcid":"https://orcid.org/0000-0002-6723-4229","observed_orcids":["https://orcid.org/0000-0002-6723-4229"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fernando Dangond","raw_affiliation_strings":["EMD Serono, Inc. Rockland MA United States","1EMD Serono, Inc. Rockland MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"1EMD Serono, Inc. Rockland MA United States","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076423610","display_name":"Anthony T. Reder","orcid":"https://orcid.org/0000-0002-6423-1495","observed_orcids":["https://orcid.org/0000-0002-6423-1495"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Reder","raw_affiliation_strings":["Department of Neurology University of Chicago Chicago IL United States","3Department of Neurology University of Chicago Chicago IL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology University of Chicago Chicago IL United States","institution_ids":["https://openalex.org/I40347166"]},{"raw_affiliation_string":"3Department of Neurology University of Chicago Chicago IL United States","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021092653","display_name":"Mark Steven Freedman","orcid":"https://orcid.org/0000-0003-1255-9701","observed_orcids":["https://orcid.org/0000-0003-1255-9701"]},"institutions":[{"id":"https://openalex.org/I153718931","display_name":"University of Ottawa","ror":"https://ror.org/03c4mmv16","country_code":"CA","type":"education","lineage":["https://openalex.org/I153718931"]},{"id":"https://openalex.org/I4388482656","display_name":"Ottawa Hospital Research Institute","ror":"https://ror.org/05jtef216","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I153718931","https://openalex.org/I2800722420","https://openalex.org/I4388482656"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Mark Freedman","raw_affiliation_strings":["University of Ottawa and the Ottawa Hospital Research Institute Ottawa ON Canada","4University of Ottawa and the Ottawa Hospital Research Institute Ottawa ON Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Ottawa and the Ottawa Hospital Research Institute Ottawa ON Canada","institution_ids":["https://openalex.org/I153718931","https://openalex.org/I4388482656"]},{"raw_affiliation_string":"4University of Ottawa and the Ottawa Hospital Research Institute Ottawa ON Canada","institution_ids":["https://openalex.org/I153718931","https://openalex.org/I4388482656"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2641,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.58429176,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"84","issue":"14_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.9440000057220459},{"id":"https://openalex.org/keywords/interferon-beta-1a","display_name":"interferon beta-1a","score":1.0},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.890999972820282},{"id":"https://openalex.org/keywords/intramuscular-administration","display_name":"intramuscular administration","score":0.9559999704360962},{"id":"https://openalex.org/keywords/no-evidence-of-disease-activity","display_name":"no evidence of disease activity","score":0.847000002861023},{"id":"https://openalex.org/keywords/gadolinium-enhancing-lesions","display_name":"gadolinium-enhancing lesions","score":0.8650000095367432},{"id":"https://openalex.org/keywords/t2-lesions","display_name":"T2 lesions","score":0.9100000262260437},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.7720000147819519},{"id":"https://openalex.org/keywords/treatment-efficacy-comparison","display_name":"treatment efficacy comparison","score":0.6769999861717224},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.6190000176429749},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.7300000190734863}],"concepts":[{"id":"https://openalex.org/C2994247566","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta","level":3,"score":0.8103059530258179},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7272292375564575},{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.7165693044662476},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.6340076923370361},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4865033030509949},{"id":"https://openalex.org/C2908698914","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta-1a","level":4,"score":0.45745670795440674},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4310978651046753},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3346688747406006},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3320106267929077},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2349112331867218},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.84.14_supplement.p7.220","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p7.220","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W582331717","https://openalex.org/W2618896926","https://openalex.org/W2592340246","https://openalex.org/W2774316186","https://openalex.org/W2072295861","https://openalex.org/W2076814339","https://openalex.org/W1490061791","https://openalex.org/W6942507519","https://openalex.org/W2039234618","https://openalex.org/W1983999022"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"compare":[2],"the":[3,42,47,142],"efficacy":[4],"of":[5,36,146,152,189,256],"interferon":[6],"beta-1a":[7],"(IFN":[8],"\u03b2-1a)":[9],"44":[10],"\u00b5g":[11,21],"given":[12,22],"subcutaneously":[13],"(SC)":[14],"3x/week":[15],"(tiw)":[16],"versus":[17,163],"IFN":[18,60,66,159,164,190,229,236],"\u03b2-1a":[19,61,67,160,165,191,230,237],"30":[20],"intramuscularly":[23],"(IM)":[24],"1x/week":[25],"(qw)":[26],"in":[27,41,91,187],"achieving":[28,138],"clinical":[29],"activity":[30,38],"free":[31],"(CAF)":[32],"and":[33,99,115,127,178,205,215,242,261],"no":[34,105,121],"evidence":[35],"disease":[37],"(NEDA)":[39],"status":[40,140,170,197,207],"EVIDENCE":[43,48],"study.":[44],"BACKGROUND:":[45],"In":[46,72],"study,":[49],"patients":[50,157,225],"with":[51,104,120,137,226],"relapsing":[52],"multiple":[53],"sclerosis":[54],"(RMS)":[55],"were":[56,79,193],"randomized":[57],"to":[58],"receive":[59],"SC":[62,161,192,231],"tiw":[63,232],"(n=339)":[64],"or":[65,83,108,148],"IM":[68,166,238],"qw":[69,239],"(n=338).":[70],"DESIGN/METHODS:":[71],"this":[73],"post":[74],"hoc":[75],"analysis,":[76],"endpoints":[77],"analyzed":[78],"CAF":[80,119,169,241],"(no":[81],"relapses":[82],"12-week":[84],"confirmed":[85],"disability":[86],"worsening":[87],"[\u88051":[88],"point":[89],"increase":[90],"Expanded":[92],"Disability":[93],"Status":[94],"Scale":[95],"score])":[96],"at":[97,112,125,171,198,208],"24":[98,113,126,173,199,210],"48":[100,128,180,217],"weeks,":[101,114],"NEDA":[102,117,139,196,243],"(CAF":[103],"gadolinium-enhancing":[106],"lesions":[107],"new/enlarging":[109,122],"T2":[110,123],"lesions)":[111,124],"modified":[116],"(mNEDA;":[118],"weeks.":[129],"Additional":[130],"ongoing":[131],"analyses":[132],"will":[133],"examine":[134],"factors":[135],"associated":[136],"within":[141],"first":[143],"12":[144,150],"weeks":[145,151,200],"treatment":[147],"following":[149],"treatment.":[153],"RESULTS:":[154],"Significantly":[155,223],"more":[156,224],"receiving":[158,228,235],"tiw,":[162],"qw,":[167],"had":[168],"Week":[172,179,209,216],"(72[percnt]":[174],"vs":[175,182,202,212,219],"58[percnt];":[176],"p<0.001)":[177,204,214],"(56[percnt]":[181],"46[percnt];":[183],"p=0.01).":[184],"Similar":[185],"results":[186],"favor":[188],"seen":[194],"for":[195],"(61[percnt]":[201],"42[percnt];":[203],"mNEDA":[206],"(66[percnt]":[211],"50[percnt];":[213],"(44[percnt]":[218],"32[percnt];":[220],"p=0.003).":[221],"CONCLUSIONS:":[222],"RMS":[227],"than":[233],"those":[234],"achieved":[240],"status.":[244],"Study":[245],"Supported":[246],"by:":[247],"EMD":[248],"Serono,":[249],"Inc.,":[250],"Rockland,":[251],"MA,":[252],"USA":[253],"(a":[254],"subsidiary":[255],"Merck":[257],"KGaA,":[258],"Darmstadt,":[259],"Germany)":[260],"Pfizer":[262],"Inc,":[263],"New":[264],"York,":[265],"NY,":[266],"USA.":[267]},"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}